Canada Pension Plan Investment Board’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-7,700
Closed -$19.8K 1488
2024
Q2
$19.8K Hold
7,700
﹤0.01% 1324
2024
Q1
$37.9K Hold
7,700
﹤0.01% 1152
2023
Q4
$67.7K Hold
7,700
﹤0.01% 1051
2023
Q3
$88.3K Buy
+7,700
New +$148K ﹤0.01% 961
2023
Q2
Sell
-167,568
Closed -$5.4M 1122
2023
Q1
$5.4M Buy
+167,568
New +$5.22M 0.01% 565
2018
Q3
Sell
-582,900
Closed -$16M 1328
2018
Q2
$16M Hold
582,900
0.03% 440
2018
Q1
$18M Hold
582,900
0.03% 446
2017
Q4
$20.8M Hold
582,900
0.04% 358
2017
Q3
$16.1M Hold
582,900
0.03% 403
2017
Q2
$15.4M Hold
582,900
0.04% 372
2017
Q1
$12.1M Hold
582,900
0.03% 409
2016
Q4
$12.1M Hold
582,900
0.04% 314
2016
Q3
$9.45M Sell
582,900
-27,400
-4% -$398K 0.03% 369
2016
Q2
$8.3M Hold
610,300
0.03% 394
2016
Q1
$10.7M Hold
610,300
0.04% 351
2015
Q4
$20.8M Hold
610,300
0.1% 162
2015
Q3
$18.2M Buy
+610,300
New +$18.5M 0.07% 235

Other funds holding RVNC

Canada Pension Plan Investment Board's RVNC Position: Q3 2024 in Review

Canada Pension Plan Investment Board sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 7,700 shares — an estimated $19.8K sold.

Canada Pension Plan Investment Board first reported a position in RVNC in Q3 2015 and held it in 17 quarters. The position peaked at $20.8M in Q4 2015. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Canada Pension Plan Investment Board reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 7,700 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $19.8K.
  • Canada Pension Plan Investment Board first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 17 quarters.
  • Canada Pension Plan Investment Board's Revance Therapeutics, Inc. position peaked at $20.8M in Q4 2015.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Canada Pension Plan Investment Board's 13F filing for Q3 2024, filed 14 Nov 2024.